Maresa Altomonte

Maresa Altomonte

Auto-generated profile, based on publicly available information

Maresa Altomonte

Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
FFFerrucci Francesco
Ferrucci Francesco
PAP. A. Ascierto
P. A. Ascierto
JPJacopo Pigozzo
Jacopo Pigozzo
MVMichele Del Vecchio
Michele Del Vecchio
MMMichele Maio
Michele Maio
CMC. Martinoli
C. Martinoli
Background Clinical responses to ipilimumab are variable in terms of onset, magnitude and duration. Upfront identification of patients who are more likely or unlikely to benefit from treatment is a major need. Patients and methods Prospectively collected data from 720 advanced melanoma patients treated with ipilimumab 3 mg/kg within the Italian expanded access programme were analyzed. The derived neutrophil-to-lymphocyte ratio (dNLR) was calculated from baseline peripheral blood cell counts, and receiver operating characteristic curve was used to evaluate the best cut-off for this marker. Patients were stratified according to dichotomized baseline absolute neutrophil counts (ANC), dNLR, and their combination. The prognostic values of ANC and dNLR for survival were assessed using multivariate Cox proportional hazard models. A subgroup analysis including LDH in the models was also performed. Results The median follow-up was 16.5 months. The optimal cut-off for dNLR was 3. Baseline ANC and dNLR were significantly associated with outcome of ipilimumab-treated melanoma patients, in terms of disease progression and death (P<0.0001 for all). Further, for each elevated variable, prognosis worsened. Patients with both ANC≥7500 and dNLR≥3 had a significantly and independently increased risk of death (HR=5.76; 95%CI: 4.29-7.75) and of progression (HR=4.10; 95%CI: 3.08-5.46) compared to patients with both lower ANC and dNLR. Patients with one of the two factors elevated displayed an intermediate risk of progression and death. The 1-year and 2-years survival rates were 2% and 0%, respectively, for patients with ANC≥7500 and dNLR≥3, and 43% and 24%, respectively, for patients with both lower ANC and dNLR. Conclusions Although these findings need to be confirmed and validated, we suggest that a neutrophil-based index may help risk-group stratification and assist disease management strategies. Further, the potential predictive value of this index for response to ipilimumab should be investigated in randomized clinical trials.

1 October 2013 in The Lancet Oncology
Verified
Journal Article
Closed access
LCLuana Calabrò
Luana Calabrò
AMAldo Morra
Aldo Morra
EFEster Fonsatti
Ester Fonsatti
OCOrnella Cutaia
Ornella Cutaia
GAGiovanni Amato
Giovanni Amato
MMMichele Maio
Michele Maio

13 January 2009 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
AGAnna Maria Di Giacomo
Anna Maria Di Giacomo
RDRiccardo Danielli
Riccardo Danielli
MGMassimo Guidoboni
Massimo Guidoboni
LCLuana Calabrò
Luana Calabrò
DCDora Carlucci
Dora Carlucci
MMMichele Maio
Michele Maio

29 September 2003 in Oncogene
Verified
Journal Article
Closed access
EFEster Fonsatti
Ester Fonsatti
MAMaresa Altomonte
Maresa Altomonte
MNMaria Rita Nicotra
Maria Rita Nicotra
PNPier Giorgio Natali
Pier Giorgio Natali
MMMichele Maio
Michele Maio

1 June 2018 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
LCLuana Calabrò
Luana Calabrò
AMAldo Morra
Aldo Morra
DGDiana Giannarelli
Diana Giannarelli
GAGiovanni Amato
Giovanni Amato
ADArmida D'Incecco
Armida D'Incecco
MMMichele Maio
Michele Maio

1 April 2015 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
LCLuana Calabrò
Luana Calabrò
AMAldo Morra
Aldo Morra
EFEster Fonsatti
Ester Fonsatti
OCOrnella Cutaia
Ornella Cutaia
CFCarolina Fazio
Carolina Fazio
MMMichele Maio
Michele Maio